1. The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair
- Author
-
Carl D. Langefeld, Pierre-Alexandre Vidi, Kurt Hodges, Sophie A. Lelièvre, Naike Salvador Moreno, Chaitali Chakraborty, Laurie L. Parker, Lance D. Miller, Paul J. Robinson, Karen M. Haas, Jing Liu, and Stephen J. Kron
- Subjects
DNA End-Joining Repair ,DNA Repair ,DNA damage ,NAR Breakthrough Article ,Down-Regulation ,Cell Cycle Proteins ,Biology ,Negative regulator ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Nuclear Matrix-Associated Proteins ,Genetics ,Humans ,DNA Breaks, Double-Stranded ,Cell Cycle Protein ,Cells, Cultured ,030304 developmental biology ,0303 health sciences ,Nucleoplasm ,HEK 293 cells ,Structural protein ,Antigens, Nuclear ,DNA Repair Pathway ,Double Strand Break Repair ,Chromatin ,Cell biology ,HEK293 Cells ,chemistry ,030220 oncology & carcinogenesis ,Nucleic acid ,Female ,Tumor Suppressor p53-Binding Protein 1 ,Corrigendum ,DNA ,Protein Binding - Abstract
P53-binding protein 1 (53BP1) mediates DNA repair pathway choice and promotes checkpoint activation. Chromatin marks induced by DNA double-strand breaks and recognized by 53BP1 enable focal accumulation of this multifunctional repair factor at damaged chromatin. Here, we unveil an additional level of regulation of 53BP1 outside repair foci. 53BP1 movements are constrained throughout the nucleoplasm and increase in response to DNA damage. 53BP1 interacts with the structural protein NuMA, which controls 53BP1 diffusion. This interaction, and colocalization between the two proteins in vitro and in breast tissues, is reduced after DNA damage. In cell lines and breast carcinoma NuMA prevents 53BP1 accumulation at DNA breaks, and high NuMA expression predicts better patient outcomes. Manipulating NuMA expression alters PARP inhibitor sensitivity of BRCA1-null cells, end-joining activity, and immunoglobulin class switching that rely on 53BP1. We propose a mechanism involving the sequestration of 53BP1 by NuMA in the absence of DNA damage. Such a mechanism may have evolved to disable repair functions and may be a decisive factor for tumor responses to genotoxic treatments.
- Published
- 2019
- Full Text
- View/download PDF